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Abstract
Brain Health Services are a novel approach to the personalized prevention of dementia. In this paper, we consider
how such services can best reflect their social, cultural, and economic context and, in doing so, deliver fair and
equitable access to risk reduction. We present specific areas of challenge associated with the social context for
dementia prevention. The first concentrates on how Brain Health Services engage with the “at-risk“ individual,
recognizing the range of factors that shape an individual’s risk of dementia and the efficacy of risk reduction
measures. The second emphasizes the social context of Brain Health Services themselves and their ability to provide
equitable access to risk reduction. We then elaborate proposals for meeting or mitigating these challenges. We
suggest that considering these challenges will enable Brain Health Services to address two fundamental questions:
the balance between an individualized “high-risk” and population focus for public health prevention and the ability
of services to meet ethical standards of justice and health equity.
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Background
The development and implementation of “precision”
Brain Health Services (BHSs) represent a novel approach
to reducing the risk of dementia in older adults. In this
paper, we consider how such services can best reflect
their social, cultural, and economic context and, in doing
so, deliver fair and equitable access to risk reduction.
Our aim is to provide a constructive critique and initiate
discussion around the challenges faced and raised by
brain health programs.
We focus on the model of the BHS as developed by
Frisoni et al. [1]. BHSs set out a model of personalized
prevention, based around individualized multidomain
interventions and educational activities and, in anticipa-
tion of potential disease-modifying therapies, around
reshaped secondary care services. Whereas those with
objective cognitive impairment are often served by exist-
ing memory clinics, BHSs extend to those without ob-
jective cognitive impairment but are concerned they are
at higher risk of developing dementia for a potentially
varying set of reasons, including family history. BHSs fea-
ture specific organization, structure and challenges [2],
and have four main missions (extensively discussed in
the pertinent papers published in this issue of Alzhei-
mer’s Research & Therapy): dementia risk profiling [3],
dementia risk communication [4], dementia risk reduc-
tion [5], and cognitive enhancement [6].
Our discussion proceeds as follows. First, we consider
the practical challenges associated with the social and
economic context for the delivery of BHSs. In each sec-
tion, we frame these around a specific challenge and
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suggest potential practical, policy and research re-
sponses. In closing, we argue that situating BHSs in their
social context requires attention to the ability of such
services to deliver access to risk reduction in a socially
just and equitable fashion.
We present two specific areas of challenge associated
with the social context for dementia prevention. The
first concentrates on how BHSs engage with the “at-risk”
individual, recognizing the range of factors that shape an
individual’s risk of dementia and the efficacy of risk re-
duction measures. The second emphasizes the social
context of BHSs themselves and their ability to provide
equitable access to risk reduction. Rather than simply
pointing out challenges, however, we introduce pro-
posals for remedying or mitigating them. Considering
these challenges would enable BHSs to address two fun-
damental questions: the balance between a “high-risk”
and “population” focus for public health prevention and
the ability of services to meet ethical standards of justice
and health equity.
The at-risk individual in social context
The social determinants of dementia risk
 Challenge. A focus on self-referring high-risk indi-
viduals within specialist BHSs does not reflect the
wider social and economic determinants of brain
health and cannot be the most effective and efficient
approach to risk reduction at a population level.
 Elaboration. An individual’s risk of developing
dementia is a consequence of their genetic
background and the accumulation of factors over
the life course [7, 8]. Globally, it is estimated that
more than a third of the incidence of dementia in
the population is due to exposure to potentially
modifiable risk factors. The age-specific incidence of
dementia is falling in many countries as a result of
improvements in childhood education, nutrition,
healthcare, and lifestyle changes [9, 10].
These findings have clear implications for the
promotion of brain health. The Lancet Commission
focuses recommendations on 12 modifiable risk
factors: the treatment of hypertension, childhood
education, exercise, social engagement, smoking and
alcohol consumption, hearing loss, depression,
diabetes, obesity, air pollution, and traumatic brain
injury [8]. Many of these risk factors may be
amenable to behavior change and lifestyle
approaches. However, among them are those that
are not easily incorporated into an approach to
brain health focused on the individual rather than
populations or groups—such as access to education
in early life or exposure to air pollution. In fact, even
factors which are often considered as “individually”
modifiable are unequally distributed, are closely
associated with wider forms of social, economic,
health, and gender inequality, and are grounded in
social and economic conditions that run through the
life course [8, 11, 12]. Importantly, they also reflect
structurally and institutionally embedded inequalities
and discrimination related to race/ethnicity—both in
the social distribution of risk factors, such as access
to education, and the representation of diverse
populations in clinical and epidemiological datasets
[13, 14].
The implications for BHSs are twofold. First,
primary prevention activities in populations have
already been shown to have significant societal
value. Thinking how to develop these sensibly within
contemporary populations would be a worthwhile
focus for research and policy. Second, a “high-risk”
focus needs to engage with social and economic
determinants of dementia risk, and their uneven
distribution across populations, as this is where the
greatest gain may be achieved in terms of future
risk reduction.
 Solution. Individualized approaches to brain health
need to explicitly account for the social and
economic distribution of risk across the life course
in order to shift population risk profiles for cognitive
decline and dementia at each life stage [15]. All
BHSs should commit to programs that are not only
individual risk reduction programs, but that aim to
address economic and social determinants of health
and disease by empowering individuals and
communities who are at greatest disadvantage.
Risk communication and behavior change
 Challenge. The concept of BHSs relies largely on
individualized risk prediction, using models derived
from a combination of lifestyle, genetic, and
biomarker information. This information forms the
basis for personalized “precision” prevention plans.
It is essential, however, that these interventions
recognize the psycho-social challenges and complex-
ity associated with behavior change and acknow-
ledge the uncertainties associated with risk
prediction models.
 Elaboration. The use of genetic, biomarker, and
lifestyle information to identify “high-risk”
individuals for “secondary prevention” is central to
the BHS model. The use of this information to make
significant differences to individual risk, however,
remains understudied. Here, there is potential to
learn from risk reduction programs in other clinical
areas. The central message of systematic reviews of
this work has been that the individualized provision
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of risk information alone has neither strong nor
consistent effects on health-related behaviors [16].
In the case of cardiovascular disease, it has been
shown that personalized risk information can im-
prove the accuracy of an individual’s perception of
their risk and may have implications for improving
clinical prescribing but, again, has little effect on the
way individuals live their lives [17]. In the case of
genetic risk information, trials of the provision of
genetic risk information have shown no or very lim-
ited effects on health behaviors [18].
For dementia itself, there is also a need to be
cognizant of the uncertainties associated with risk
information. These uncertainties reflect the
limitations of the evidence base that informs current
prediction models when applied to individuals and
have consequences for those acting upon them [19].
Thus, for example, there is evidence of differing
effects of ancestry on genetic risk but also significant
under-representation of racially and ethnically di-
verse populations in studies of imaging and genom-
ics, as well as clinical trials [20–23]. Uncertainties
are likely to be particularly exacerbated among those
attending BHSs from the general population, rather
than traditional memory clinic populations or
among those with a diagnosis of mild cognitive im-
pairment [24–26].
Sub-analyses of the FINGER and MAPT studies
suggest that a multimodal programs of risk
reduction may have some, limited in size, value for
high-risk individuals, particularly those at greater
genetic risk (i.e., APOE ɛ4 carriers) [27] or with
brain amyloidosis [28]. However, these were not the
primary endpoints and such findings must be con-
firmed in targeted studies. Together, the current risk
reduction interventions and the apparently limited
value of approaches based solely on risk communi-
cation suggest there is an opportunity for work on
dementia prevention to learn from, rather than re-
peat, the mistakes of other fields. To make a signifi-
cant difference, BHSs should have a robust model of
the complexity of health behaviors and their change
[29].
 Solution. Approaches to risk reduction that rely on
individualized risk prediction leading to behavior
changes are likely to be of limited effectiveness.
Indeed, the vast bulk of evidence about changing
behavior takes account of the fact that much
decision making is automatic, and that changing
behavior involves a combination of capability,
motivation, and opportunity [30]. This may include
changes to the environment to enhance the capacity
for healthy behaviors to occur. For example, there is
some evidence that approaches to CVD risk
reduction focusing on a range of community based
approaches may not only be efficacious but also
reduce inequalities in health outcomes [31, 32]. In
the case of dementia prevention, this may include
the creation of life-course environments that en-
courage physical activity, good nutrition, educational
opportunities, social engagement, and a healthy
physical environment.
In engaging with uncertainty, the actual nature of
the evidence base, rather than the hyperbole, for
prediction models and individualized risk reduction
programs should be discussed with members of the
public and patients who seek such approaches, in
relation to their age, gender, and race/ethnicity, with
regard to short-, medium-, and long-term prospects
of benefit, known harms, and likely cost.
The BHSs in a social context
Access to BHSs
 Challenge. Specialist BHSs risk compounding issues
of access associated with existing clinical services,
limiting their value to disadvantaged populations.
 Elaboration. Expanding services targeting the
“worried well” risk reinforcing the “inverse care law,”
targeting those already well-served by health care
and preventative health services, many of whom
would probably have relatively little likelihood of
benefitting and are probably most likely to have op-
timal brain health [33]. Where these services are re-
imbursed, it is important to consider the trade-offs
with services that are not being implemented, with
better evidence bases that might achieve more for
more people [34]. Where private health care pro-
viders offer services, potential customers who feel
they may be beneficial should be informed about the
state of evidence and its limitations. The recent his-
tory of direct-to-consumer genetic testing and “brain
training” tools shows that there are likely to be many
products and services whose marketing may lead in-
dividuals to assume a health benefit that is not justi-
fied by the evidence base [35, 36].
In addition, interventions that require an individual
to draw on their own resources—whether social,
economic, or psychological—tend to
disproportionately benefit those with more of these
resources [37]. This can result in the accumulation
of disadvantage—both through exposure to risk, as
discussed above, and in terms of access to testing
and diagnostic services.
Access to memory clinics, and even dementia
services, is unequally distributed within and between
countries, and is low around the world, varying
significantly by country. Some such inequalities are a
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result of the geographical distribution of services
within countries, particularly where they are
concentrated in urban areas [38, 39]. People living in
rural areas may thus have less access to specialist
dementia services and post-diagnostic support, ei-
ther because they do not exist or are inaccessible by
public transport, and there may be a greater em-
phasis on the role of primary care [40].
Further, in the UK and USA, access to a diagnosis
has been shown to be associated with older age,
male gender, and higher level of education and
socio-economic status including income [41–43].
Those from less deprived socio-economic groups are
more likely to be initiated on anti-dementia drugs
than the most deprived and may also present at
clinic earlier in the progression of symptoms [44,
45]. Race/ethnicity is also associated with access. In
the USA, those from non-Hispanic Black and His-
panic populations are more likely to have a missed
or delayed diagnosis, less likely to access diagnostic
services later, and be less likely to access medication
or research trials [46–48]. Similar findings have been
found in the UK for Asian men and women, and
Black men [43, 49, 50]. Importantly though, data on
race/ethnicity is often not collected—in a study
based on a representative sample of UK primary care
records, race/ethnicity was far more likely to be
missing from records than information on
deprivation [49]. These lacunae in the data present
challenges in understanding who is accessing, and
who is excluded, from BHSs, and further exacerbate
the biases in data discussed above.
Further, access to BHSs is likely to be shaped by
cultural framings of both dementia and risk.
Available evidence suggests cultural factors that
shape access to memory clinics, and, while specific
evidence is lacking, it seems likely they would
similarly affect the distribution of those who attend
BHSs. Such cultural factors may differ by country
and between racial or ethnic groups. Qualitative
research, for example, suggests potential cultural
differences related to the recognition or acceptance
of dementia, or hesitations in seeking a diagnosis
among minority ethnic groups, such that medical
help may not be sought and dementia seen as a
private problem, associated with significant social
stigma [51–54]. In the USA, public expectations
related to learning dementia risk may also reflect
concerns about employment and insurance
discrimination, considerations that, as Frisoni et al.
rightly point out, impact on the decision to
communicate risk status. Such considerations also
shape how people access services [55].
To ensure that BHSs address and do not exacerbate
inequalities in access, we need robust trial evidence
before extending reimbursed BHSs to asymptomatic
individuals. The overall benefit to societies of
targeted early detection services has not yet been
proven in clinical trials and the only international
study of screening did not reveal any tangible
benefits [34]. It is important to acknowledge the
existing clinical context for memory clinics that
themselves were not developed out of an evidence
base but out of a need to identify individuals at an
earlier stage of dementia or cognitive impairment
from which to recruit to trials.
Here again, the development of the BHSs might
usefully draw on the experience of other areas, such
as the introduction of routine health checks in the
field of cardiovascular disease prevention. The
introduction of general health checks for reducing
illness or mortality has been evaluated as unlikely to
be beneficial [56]. In fact, both health checks and
individualized behavior change approaches may have
potentially negative impacts on overall population
health equity [37, 57]. In contrast, evaluations of
interventions in healthy eating suggest that those that
focus “upstream,” for example by intervening in price,
are likely to reduce inequalities [32]. The development
of brain health programs should consider and
evaluate the impact of such programs on health
inequalities and the potential for alternative
approaches that may reduce inequity. This offers the
opportunity to better understanding the impact of
interventions across social inequalities and to increase
the potential for genuinely beneficial interventions
that consider whole systems and the complex realities
of public health [58]. For example, modeling
incorporating an explicit emphasis on equity suggests
that targeting health checks to areas of
disadvantage—using health care records to identify
those at greatest risk of adverse outcomes—may make
them more efficacious, beneficial and cost-effective
[57].
 Solution. To be of value, investment or
reimbursement for individualized approaches to risk
reduction must evaluate the value for those they
represent in terms of long-term brain health, where/
whether an individualized approach will lead to suf-
ficient risk reduction to be systematically supported,
and what the implications are in terms of equity.
This includes the routine collection and evaluation
of socio-economic data related to the impact of
BHSs. It also involves the exploration of interven-
tions whose ambition is to address systemic and
population-level challenges and approaches to
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delivery that engage with the cultural, religious, eth-
nic, and racial diversity of the populations they
serve.
Achieving just brain health
In the preceding sections, we have suggested that the
challenges for BHSs, when considered in their social
context, are considerable but not insurmountable. These
challenges, and the remedies we have proposed, are
summarized in Table 1. In closing, we consider the ben-
efits of addressing them.
The first relates to the balance between individualized
“high risk” and population prevention strategies. The
former may have more significant impacts on individ-
uals, whereas the latter may have more modest individ-
ual impacts but a greater impact across the population.
Further, shifting the norm of behaviors across the popu-
lation may have a subsequent impact on what is consid-
ered as “high-risk” behavior. Thus, high-risk individuals
may be more likely to take physical exercise or reduce
smoking if this is considered to be normal [59]. As Fri-
soni et al. note, following Rose, high-risk and population
strategies are not inherently exclusive [1, 60]. The bene-
fits of population prevention may sit alongside those tar-
geting individuals with pathological changes associated
with increased risk of dementia. However, as Rose also
recognized, the complementarity of these approaches re-
lies on a lack of competition for resources. In the
current environment for healthcare where competition
for resources is intense, a resource intensive high-risk
approach inevitably limits the possibilities for population
measures—even when the overall benefit of the latter
may be greater.
The development of BHSs thus requires addressing a
wider range of issues than currently considered within
the “ethics” of BHSs. Discussion of the ethics of demen-
tia prevention has been dominated by a focus on auton-
omy, particularly the right of individuals to know, or not
to know, their risk [1, 61]. The challenges presented here
emphasize the critical and compelling importance of
widening this discussion, particularly as the concerns of
the memory clinic and clinical ethics encounter those of
population health, public health, and societal ethics. It
has been recognized that it is essential that efforts to
prevent dementia “leave no one behind” [62]. Social just-
ice must be embedded as a core value and guiding
principle for brain health programs [63, 64]. This means
improving health to improve well-being, by focusing on
the needs of the most disadvantaged, to ensure the fair
distribution of common advantages and the sharing of
common burdens. At heart, following Beauchamp’s
framing of public health ethics, it requires thinking
about and reacting to the problem of brain health as
“primarily collective problems of the entire society” [64].
Conclusions
BHSs that focus on the delivery of personalized risk
scores and interventions targeted at “high risk” individ-
uals may have potential as an approach limited to redu-
cing risk in some sections of the population. However,
this must be developed hand in glove with improving
the means of reducing the overall population burden of
dementia through life-course and broader societal mea-
sures. It is these measures that will change the incidence
and prevalence of dementia, as well illustrated in the last
50 years. It is therefore essential that those who invest in
the development of BHSs aimed at individualized ser-
vices consider the just allocation of resources between
approaches. While high-risk and population approaches
can be complementary, they risk competing for scarce
resources, particularly given the resource-intensiveness
of clinical risk assessment and follow-up. Without atten-
tion to the factors discussed here, an approach focusing
primarily on high-risk populations is likely to struggle to
deliver fair and equitable access to services or to risk
reduction.
Abbreviation
BHS: Brain Health Service
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